Ryvu Therapeutics (STU:9Y4) E10: €1.33 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:9Y4 Ryvu Therapeutics SA STU:9Y4
68 GF Score
Price €3.31
GF Value €10.19
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Ryvu Therapeutics E10?

Ryvu Therapeutics STU:9Y4 -0.45% 68 E10 is €1.33 as of Mar. 2026. GuruFocus rates STU:9Y4 with a GF Score™ of 68/100 and a GF Value™ of €10.19 (Possible Value Trap). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Ryvu Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.114. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €1.33 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Ryvu Therapeutics's average E10 Growth Rate was -3.20% per year. During the past 3 years, the average E10 Growth Rate was -9.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Ryvu Therapeutics was 3.20% per year. The lowest was -9.10% per year. And the median was -2.95% per year.

As of today (2026-07-27), Ryvu Therapeutics's current stock price is €3.305. Ryvu Therapeutics's E10 for the quarter that ended in Mar. 2026 was €1.33. Ryvu Therapeutics's Shiller PE Ratio of today is 2.48.

During the past 13 years, the highest Shiller PE Ratio of Ryvu Therapeutics was 8.96. The lowest was 2.31. And the median was 6.40.


Ryvu Therapeutics  (STU:9Y4) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Ryvu Therapeutics's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=3.305/1.33
=2.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Ryvu Therapeutics was 8.96. The lowest was 2.31. And the median was 6.40.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Ryvu Therapeutics E10 Related Terms


Ryvu Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for Ryvu Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ryvu Therapeutics E10 Chart

Ryvu Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 1.61 1.84 1.75 1.28

Ryvu Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.42 1.33 1.33 1.28 1.33

STU:9Y4 vs VRTX, REGN, RVMD: E10 Comparison

For the Biotechnology subindustry, Ryvu Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ryvu Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ryvu Therapeutics's Shiller PE Ratio falls into.


STU:9Y4
68GF Score
Ryvu Therapeutics SA STU:9Y4
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ryvu Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ryvu Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.114/163.0700*163.0700
=-0.114

Current CPI (Mar. 2026) = 163.0700.

Ryvu Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201606 -0.017 99.552 -0.028
201609 0.045 99.064 0.074
201612 0.060 100.366 0.097
201703 9.033 101.018 14.582
201706 0.046 101.180 0.074
201709 0.015 101.343 0.024
201712 -0.045 102.564 -0.072
201803 0.283 102.564 0.450
201806 -0.058 103.378 -0.091
201809 -0.166 103.378 -0.262
201812 -0.416 103.785 -0.654
201903 -0.138 104.274 -0.216
201906 -0.166 105.983 -0.255
201909 -0.056 105.983 -0.086
201912 4.451 107.123 6.776
202003 -0.062 109.076 -0.093
202006 -0.062 109.402 -0.092
202009 -0.166 109.320 -0.248
202012 -0.140 109.565 -0.208
202103 -0.169 112.658 -0.245
202106 -0.302 113.960 -0.432
202109 -0.284 115.588 -0.401
202112 -0.228 119.088 -0.312
202203 -0.320 125.031 -0.417
202206 -0.457 131.705 -0.566
202209 -0.137 135.531 -0.165
202212 -0.114 139.113 -0.134
202303 -0.183 145.950 -0.204
202306 -0.274 147.009 -0.304
202309 -0.183 146.113 -0.204
202312 -0.274 147.741 -0.302
202403 -0.183 149.044 -0.200
202406 -0.320 150.997 -0.346
202409 -0.252 153.439 -0.268
202412 -0.343 154.660 -0.362
202503 -0.252 157.021 -0.262
202506 -0.343 157.509 -0.355
202509 -0.252 158.000 -0.260
202512 -0.183 158.320 -0.188
202603 -0.114 163.070 -0.114

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €1.33 mean?
Ryvu Therapeutics (STU:9Y4) has a E10 of €1.33 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Ryvu Therapeutics and its competitors.
Is Ryvu Therapeutics' E10 too high?
Ryvu Therapeutics' current E10 is €1.33. Overall, Ryvu Therapeutics has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' E10 compare to VRTX and REGN?
Ryvu Therapeutics' E10 of €1.33 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Ryvu Therapeutics and its competitors. Ryvu Therapeutics's current E10 is €1.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ryvu Therapeutics (STU:9Y4) is currently considered Possible Value Trap. The stock's GF Value™ is €10.19, compared to a current price of €3.31 — trading 67.6% below its estimated fair value. The current E10 is €1.33. Ryvu Therapeutics' overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Ryvu Therapeutics (STU:9Y4), the current E10 is €1.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ryvu Therapeutics (STU:9Y4) Overvalued in 2026?

Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued. The current stock price of €3.31 is trading 67.6% below its estimated GF Value™ of €10.19. GuruFocus considers Ryvu Therapeutics to be Possible Value Trap.

Key valuation signals for STU:9Y4:

  • E10: €1.33
  • GF Value™: €10.19 vs. price of €3.31 (67.6% below fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the STU:9Y4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ryvu Therapeutics Business Description

Other Exchanges RVU:Poland
Address Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
68GF Score

Get the complete analysis for STU:9Y4

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.31
Price
€10.19
GF Value